Regulus Therapeutics Inc (NASDAQ:RGLS) has earned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $2.75.
A number of research firms have commented on RGLS. Zacks Investment Research cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Chardan Capital reissued a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Leerink Swann started coverage on shares of Regulus Therapeutics in a report on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, December 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th.
Regulus Therapeutics (NASDAQ RGLS) opened at $1.16 on Friday. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $1.95. The company has a market cap of $116.57, a P/E ratio of -0.87 and a beta of 1.72.
Institutional investors and hedge funds have recently made changes to their positions in the company. NEA Management Company LLC bought a new stake in shares of Regulus Therapeutics in the 3rd quarter worth approximately $13,737,000. Victory Capital Management Inc. bought a new stake in shares of Regulus Therapeutics in the 3rd quarter worth approximately $347,000. Goldman Sachs Group Inc. lifted its holdings in shares of Regulus Therapeutics by 189.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 240,890 shares during the last quarter. Candriam Luxembourg S.C.A. bought a new stake in shares of Regulus Therapeutics in the 3rd quarter worth approximately $750,000. Finally, South Dakota Investment Council lifted its holdings in shares of Regulus Therapeutics by 37.1% in the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after acquiring an additional 492,969 shares during the last quarter. Hedge funds and other institutional investors own 57.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/24/regulus-therapeutics-inc-rgls-given-consensus-recommendation-of-hold-by-analysts.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.